Status:
UNKNOWN
VEGFRs Predict Bevacizumab Benefit in Advanced Non Small Cell Lung Cancer
Lead Sponsor:
Li Liu
Conditions:
Non Small Cell Lung Cancer
Brain Metastasis
Eligibility:
All Genders
18-75 years
Brief Summary
a. VEGFRs may be the biomarker which can predict the effect of bevacizumab in non small cell lung cancer
Detailed Description
1. non small cell lung cancer (non squamous carcinoma) 2. ECOG 0-1 3. from 18-75 years old
Eligibility Criteria
Inclusion
- non squamous cell non small cell lung cancer
- with measurable disease
- ECOG 0-1
Exclusion
- \- patients received surgery in recent 4 weeks
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT01891708
Start Date
June 1 2013
End Date
December 1 2018
Last Update
July 3 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China, 430071